Sample & Assay Technologies Bank Of America Merrill Lynch .
QIAGENSample & Assay TechnologiesBank of America Merrill LynchHealth Care ConferenceNew York, May 11, 2010Roland Sackers, CFO-1-Sample & Assay Technologies
Forward Looking StatementsSafe Harbor Statement: Certain of the statements contained in this presentation may be consideredforward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, asamended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that anyof the statements contained herein relating to QIAGEN's products and markets and operating results areforward-looking, such statements are based on current expectations that involve a number of uncertaintiesand risks. Such uncertainties and risks include, but are not limited to, risks associated with management ofgrowth and international operations (including the effects of currency fluctuations), variability of operatingresults, the commercial development of the DNA sequencing, genomics and synthetic nucleic acid-relatedmarkets, as well as the nucleic acid-based molecular diagnostics, applied testing markets and geneticvaccination and gene therapy markets, competition, rapid or unexpected changes in technologies,fluctuations in demand for QIAGEN's products (including fluctuations from certain events including funding,budgets, and others), difficulties in successfully adapting QIAGEN’s products to integrated solutions andproducing such products, the ability of QIAGEN to identify and develop new products and to differentiate itsproducts from competitors, the management of intellectual property, and the integration of acquisitions oftechnologies and businesses. In addition certain statements contained in this news release are based oncompany assumptions, including, but not limited, to revenue allocations based on business segments and/orcustomer classes. For further information, refer to the discussion in reports that QIAGEN has filed with orfurnished to the U.S. Securities and Exchange Commission (SEC).Regulation G: The following slides contain certain summary information about QIAGEN N.V.’s sales, grossprofit, operating income, net income, and earnings per share over a specific period and the comparableperiod, which information is presented on a “non-GAAP financial measures” basis rather than in accordancewith U.S. generally accepted accounting principles (GAAP). Please review QIAGEN’s press releases forinformation on the company’s operating income, net income, and earnings per share for these periodspresented on a GAAP basis. Such GAAP-basis information will also be contained in the company’s reportson Form 20-F or Form 6-K to be filed with or furnished to the U.S. Securities and Exchange Commission.-2-Sample & Assay Technologies
QIAGEN at a GlanceIntroRevenues1:2009: US 1.010 MNet income2: 2009: US 200 MEPS2:2009: US 0.9304–09 CAGR: 23%04–09 CAGR 28%04–09 CAGR: 19%Product Range: 500 consumable products Sample Technologies: to collect, separate, purify,isolate, stabilize and store samples Assay Technologies: to make such isolated targetinformation (DNA, RNA, proteins, etc.) visible Instrumentation for above consumablesCustomers: 400,000 Academic research Pharma/Biotech Applied testing (veterinary, forensics etc.) Molecular diagnosticsIP (12/09): 2,100 patents(783 issued, 843 pending, 550 licensed)Employees: 3,500 employees based in 35 subsidiaries(1) Revenues 2004 excluding synthetic DNA business sold in Q2 2004.(2) Excluding acquisition, integration and relocation related charges as well as amortization ofacquired IP and equity-based compensation (SFAS 123R).-3-Sample & Assay Technologies
Sample & Assay TechnologiesIntroGolgi apparatus, Glycoproteins, Microtubules, Mitochondria, Mitochondrial nucleic acids, Vacuoles, Talin, Nucleolus, Polymerases, Ceramides, Chromosomes, Chromatin, mRNA,Cytoplasm, Leucocytes, Sugars, Lipids, Salts, Urea, Carbonic acids, Cofactors, Precursors, Hemoglobins, Erythrocytes, Monocytes, Smooth endoplasmatic reticulum, Macrophages,Thrombocytes, Platelets, Lymphocytes, Basophils, Eosinophils, Neutrophils, Megacaryocytes, Plasma, Clotting factors, Actin, Microfilaments, Serum, Fibrin, Lysosomes, Ezrin, DNA,Hemaglobins, Heptaglobins, Transferrin, Fibrinogen, Serum albumin, tRNA, Salts, Polymerases, Centrioles, Immunoglobulins, Carrier proteins, Cytokines, Angiotensins, Chemokines,Bradykines, Plasma membranes, Ribosomes, Actin, Vesicles, DNA, Complement components, Nuclei, Rough endoplasmatic reticulum, Nucleoli, Golgi apparatus, Glycoproteins,Microtubules, Mitochondria, Mitochondrial nucleic acids, Vacuoles, Talin, Nucleolus, Polymerases, Ceramides, Chromosomes, Chromatin, mRNA, Cytoplasm, Leucocytes, Sugars,Lipids, Salts, Urea, Carbonic acids, Cofactors, Precursors, Hemoglobins, Erythrocytes, Monocytes, Smooth endoplasmatic reticulum, Macrophages, Thrombocytes, Platelets,Lymphocytes, Basophils, Eosinophils, Neutrophils, Megacaryocytes, Plasma, Clotting factors, Actin, Microfilaments, Serum, Fibrin, Lysosomes, Ezrin, Hemaglobins, Heptaglobins,Transferrin, Fibrinogen, Serum albumin, tRNA, Salts, Polymerases, Centrioles, DNA, Immunoglobulins, Carrier proteins, Cytokines, Angiotensins, Chemokines, Bradykines, Plasmamembranes, Ribosomes, Actin, Vesicles, Complement components, Nuclei, Rough endoplasmatic reticulum, Nucleoli, Golgi apparatus, Glycoproteins, Microtubules, Mitochondria,Mitochondrial nucleic acids, Vacuoles, Talin, Nucleolus, Polymerases, Ceramides, Chromosomes, Chromatin, mRNA, Cytoplasm, Leucocytes, Sugars, Lipids, Salts, Urea, Carbonicacids, Cofactors, Precursors, Hemoglobins, Erythrocytes, Monocytes, Smooth endoplasmatic reticulum, Macrophages, Thrombocytes, Platelets, Lymphocytes, Basophils, Eosinophils,Neutrophils, Megacaryocytes, Plasma, Clotting factors, Actin, Microfilaments, Serum, Fibrin, Lysosomes, Ezrin, DNA, Hemaglobins, Heptaglobins, Transferrin, Fibrinogen, Serumalbumin, tRNA, Salts, Polymerases, Centrioles, Immunoglobulins, Carrier proteins, Cytokines, Angiotensins, Chemokines, Bradykines, Plasma membranes, Ribosomes, Actin,Vesicles, Complement components, Nuclei, Rough endoplasmatic reticulum, Nucleoli, Golgi apparatus, Glycoproteins, Microtubules, Mitochondria, Mitochondrial nucleic acids,Vacuoles, Talin, Nucleolus, Polymerases, Ceramides, Chromosomes, Chromatin, mRNA, Cytoplasm, Leucocytes, Sugars, Lipids, Salts, Urea, Carbonic acids, Cofactors, Precursors,Hemoglobins, Erythrocytes, Monocytes, Smooth endoplasmatic reticulum, Macrophages, Thrombocytes, Platelets, Lymphocytes, Basophils, Eosinophils, Neutrophils, Talin, .ComplexsampleGolgi apparatus, Glycoproteins, Microtubules, Mitochondria, Mitochondrial nucleic acids, Vacuoles, Talin, Nucleolus, Polymerases, Ceramides, Chromosomes, Chromatin, mRNA,Cytoplasm, Leucocytes, Sugars, Lipids, Salts, Urea, Carbonic acids, Cofactors, Precursors, Hemoglobins, Erythrocytes, Monocytes, Smooth endoplasmatic reticulum, Macrophages,Thrombocytes, Platelets, Lymphocytes, Basophils, Eosinophils, Neutrophils, Megacaryocytes, Plasma, Clotting factors, Actin, Microfilaments, Serum, Fibrin, Lysosomes, Ezrin, DNA,Hemaglobins, Heptaglobins, Transferrin, Fibrinogen, Serum albumin, tRNA, Salts, Polymerases, Centrioles, Immunoglobulins, Carrier proteins, Cytokines, Angiotensins, Chemokines,Bradykines, Plasma membranes, Ribosomes, Actin, Vesicles, DNA, Complement components, Nuclei, Rough endoplasmatic reticulum, Nucleoli, Golgi apparatus, Glycoproteins,Microtubules, Mitochondria, Mitochondrial nucleic acids, Vacuoles, Talin, Nucleolus, Polymerases, Ceramides, Chromosomes, Chromatin, mRNA, Cytoplasm, Leucocytes, Sugars,Lipids, Salts, Urea, Carbonic acids, Cofactors, Precursors, Hemoglobins, Erythrocytes, Monocytes, Smooth endoplasmatic reticulum, Macrophages, Thrombocytes, Platelets,Lymphocytes, Basophils, Eosinophils, Neutrophils, Megacaryocytes, Plasma, Clotting factors, Actin, Microfilaments, Serum, Fibrin, Lysosomes, Ezrin, Hemaglobins, Heptaglobins,SampleTechnologiesTransferrin, Fibrinogen, Serum albumin, tRNA, Salts, Polymerases, Centrioles,DNA, Immunoglobulins, Carrier proteins, Cytokines, Angiotensins, Chemokines, Bradykines, Plasmamembranes, Ribosomes, Actin, Vesicles, Complement components, Nuclei, Rough endoplasmatic reticulum, Nucleoli, Golgi apparatus, Glycoproteins, Microtubules, Mitochondria,Mitochondrial nucleic acids, Vacuoles, Talin, Nucleolus, Polymerases, Ceramides, Chromosomes, Chromatin, mRNA, Cytoplasm, Leucocytes, Sugars, Lipids, Salts, Urea, Carbonicacids, Cofactors, Precursors, Hemoglobins, Erythrocytes, Monocytes, Smooth endoplasmatic reticulum, Macrophages, Thrombocytes, Platelets, Lymphocytes, Basophils, Eosinophils,Neutrophils, Megacaryocytes, Plasma, Clotting factors, Actin, Microfilaments, Serum, Fibrin, Lysosomes, Ezrin, DNA, Hemaglobins, Heptaglobins, Transferrin, Fibrinogen, Serumalbumin, tRNA, Salts, Polymerases, Centrioles, Immunoglobulins, Carrier proteins, Cytokines, Angiotensins, Chemokines, Bradykines, Plasma membranes, Ribosomes, Actin,Vesicles, Complement components, Nuclei, Rough endoplasmatic reticulum, Nucleoli, Golgi apparatus, Glycoproteins, Microtubules, Mitochondria, Mitochondrial nucleic acids,Vacuoles, Talin, Nucleolus, Polymerases, Ceramides, Chromosomes, Chromatin, mRNA, Cytoplasm, Leucocytes, Sugars, Lipids, Salts, Urea, Carbonic acids, Cofactors, Precursors,Hemoglobins, Erythrocytes, Monocytes, Smooth endoplasmatic reticulum, Macrophages, Thrombocytes, Platelets, Lymphocytes, Basophils, Eosinophils, Neutrophils, Talin, .PureAnalyteDNATarget e & Assay Technologies
Typical Products: From Sample to ResultsSample & Assay Technologies on Automated PlatformsSample TechnologiesIntroAssay TechnologiesFully Automated Platforms-5-Sample & Assay Technologies
Sample and Assay TechnologiesIntroTechnology LeadershipSales StrengthMDxAppl. TestingPharmaBiomedicalAcademiaInside SalesMARKETSE-commerceGrowth 0.00020.00001993 1994 1995 1996 1997 1998 1999 2000 2001-6-Sample & Assay Technologies
Sample and Assay TechnologiesTechnologyLeadershipTechnology LeadershipSales StrengthMDxAppl. TestingPharmaBiomedicalAcademiaInside SalesMARKETSE-commerceGrowth 0.00020.00001993 1994 1995 1996 1997 1998 1999 2000 2001-7-Sample & Assay Technologies
Technology and Innovation LeaderTechnologyLeadershipR&D at QIAGEN:Investment: Approx. 12% of salesPeople: 700 employees in R&DMultiple locations: Germany U.S. Switzerland Singapore ChinaMultiple disciplines: Chemistry Biology Physics Engineering and othersFast, proven innovation cycles:Stable 4-5% revenue growth fromnew products launched in last 12 months.-8-Sample & Assay Technologies
Significant Sales and Marketing PowerSales StrengthTechnology LeadershipSales StrengthMDxAppl. TestingPharmaBiomedicalAcademiaInside SalesMARKETSE-commerceGrowth 0.00020.00001993 1994 1995 1996 1997 1998 1999 2000 2001-9-Sample & Assay Technologies
QIAGEN’s Global FootprintSales StrengthAmericasApprox. 47% of SalesEuropeApprox. 37% of SalesAsiaApprox. 14% of SalesRest of WorldApprox. 2% of SalesQ1 2010 percentage of salesbased on constant exchange ratesSPECIALISTSSales ChannelsMDx/Companion DxApplied Testing 1020 PharmaBiomedicalinAcademia 500inMARKETSOthers- 10 -Sample & Assay Technologies
QIAGEN‘s Organic GrowthSustainable and Industry LeadingSales StrengthOrganic Growth Rate Development16%14%12%10%8%6%4%QIAGENIndustry average2%0%200420052006200720082009Outperforming the IndustryIndustry data includes: Illumina, Luminex, Cepheid, Techne, GenProbe, Sigma Aldrich, Bio Rad, Mettler, Meridian,Beckman, Waters, Becton Dickinson, Roche, Thermo, Millipore, Bruker, Celera, Affymetrix, Immucor, QIAGEN, Tecan,Life Technologies- 11 -Sample & Assay Technologies
QIAGEN is Addressing Key Growth MarketsGrowth DriversTechnology LeadershipSales StrengthMDxAppl. TestingPharmaBiomedicalAcademiaInside SalesMARKETSE-commerceGrowth 0.00020.00001993 1994 1995 1996 1997 1998 1999 2000 2001- 12 -Sample & Assay Technologies
Leading Position - Multiple Growth DriversGrowth DriversMolecularDiagnostics Prevention Profiling PersonalizedHealthcare Point of NeedAppliedTesting VeterinaryForensicBio defenseFoodSAMPLETechnologiesLife ScienceResearchPharmaceuticalIndustry Discovery Development Public PrivateASSAYTechnologiesProduct and Technology Continuum- 13 -Sample & Assay Technologies
Molecular DiagnosticsPrevention - Profiling - Personalized Healthcare - Point of NeedGrowth DriversMarket Situation High market growth 15% New areas emerging: companion diagnostics, point of need MDx allows significant cost reduction in healthcareQIAGEN‘s Position Platforms for all laboratory sub-segments(from prevention to point of need) Technology scales across all platforms Broad assay portfolio : 15 PMA/510K, 40 CE marked, 10 SFDA Strong brand, good reputation, powerful infrastructureOpportunities New platform launches 2010 - 2012 Full assay portfolio, many assays in pipeline Personalized medicine and point of need testing- 14 -Sample & Assay Technologies
Global In Vitro Diagnostics MarketBy SegmentGrowth DriversIn Vitro DiagnosticsEstimated market volume: US 33B (2006)CAGR 2006 – 2010: 7%Molecular DiagnosticsEstimated market volume: US 2.4 billion (2006)CAGR 2006 – 2010: 17%OtherCAGR 3.5%HematologyCAGR 3.9%ClinicalChemistryCAGR 2.6%MolecularDiagnosticsUS 2.4BCAGR 17.0%Immuno-assaysCAGR 4.7%Blood GlucoseCAGR 11.5%Blood BanksOthersOncologyGeneticTestingMicrobiologyCAGR 5.7%HemostasisCoagulationCAGR 10.2%ViralInfectionsNon-ViralInfectionsPoint of CareCAGR 10.9%MDx: Fastest Growing Segment in In Vitro DiagnosticsNote: IVD market estimates vary by source and range between 29B– 35BSource: RBC Capital Markets, Nature Biotechnology (August 2006), Digene internal reports, Recap, Kalorama, BioCentury, L.E.K. Analysis- 15 -Sample & Assay Technologies
QIAGEN’s 4 “P” Framework in MDxGrowth DriversLABORYTORY BASED TESTINGPreventionAssayTechnologiesInstrumentsAssay DesignProfilingPOINT OF NEEDPersonalizedHealthcareAsymptomatic patientsGoal: Early detectionSymptomatic patientsGoal: ConfirmPre-diagnosed patientsGoal: Guide therapyRapid turnaround neededNo laboratory reachableGoal: fast result, on spotNarrow portfolioHigh volume/ 20/assayBroad portfolioHigh value,low volumeGrowing portfolioHigh value,low volumeEmerging segmentInstrument 2k,Assays: 3-30Examples HPV Chlamydia/NG 5 additional assays inpipeline More to comeExamples: CMV EBV HBV HIV HCV InfluenzaExamples KRAS EGFR B-RAF PI3K PathogenGenotypingExamples careHPV HAI InfluenzaHigh throughputContinuous loadRandom accessContinuous loadRandom accessContinuous loadPortable test systems,Rapid turn around 2hrsQIAensembleQIAsymphonyQIAsymphonyTBAFast, typically isothermalamplification or no ampPCRPyrosequencingPCRPyrosequencingIsothermal amplification- 16 -Sample & Assay Technologies
QIAGEN in Molecular DiagnosticsMigrating to Fully Automated SolutionsPREVENTIONPROFILINGGrowth DriversPERSONALIZEDHEALTHCAREPOINT OF NEED2008-2009Semi ey assays 2010FullyAutomatedFullyintegratedAssay breadth- 17 -Sample & Assay Technologies
Applied TestingMultiple Segments, Strong PotentialGrowth DriversMarket Situation Use of molecular methods increasing Market growth 15 %QIAGEN‘s Position Focus segments: genetic ID, veterinary Growing assay portfolio Complete platformsOpportunities Platform strength Geographic expansion- 18 -Sample & Assay Technologies
Pharmaceutical IndustryPartner From Discovery Through Drug Development to PHCGrowth DriversMarket Situation Pharma development continues strong Discovery soft, impacted by mergers and cost cutting Links in development into PHC and CDxQIAGEN‘s Position Perfect partner from discovery to companion diagnostics Pharma net sales: 50% development, 50% discoveryOpportunities Content-based approach (disease/pathway testing panels) Companion diagnostics New platforms (QIAsymphony RGQ)- 19 -Sample & Assay Technologies
Academic MarketsSource of InnovationGrowth DriversMarket Situation Focus on innovation (stimulus packages U.S., Europe) Scientific knowledge in Life Sciences increasing exponentially New hot topics emerging faster and fasterQIAGEN‘s Position Focused on leadership in core markets Among fastest growing companies in academic market Strong brand and good reputationOpportunities Innovation and quality leader High growth areas: e.g. biomarker discovery Stimulus packages- 20 -Sample & Assay Technologies
QIAGEN GroupRevenue and EPS Growth 2004 - 20091100CAGR2004-2009 23%FinancialsRevenues10001010893900in US AGR2004-2009 19%20062007EPS adjusted0.90in US 390.300.200.100.002004200520062007200820092004 revenues excluding synthetic DNA business, sold in Q2 2004.All figures excluding business integration and relocation related charges as well asamortization of acquired IP and equity-based compensation (SFAS 123R).- 21 -Sample & Assay Technologies
QIAGEN GroupOperating Cash Flow and Free Cash Flow 2004 - 2009250Operating Cash flow200in US 4200520020062007Free Cash flowin US 052006200720082009Free cash flow computed using net cash from operating activities less capital expenditures.- 22 -Sample & Assay Technologies
Key Investment ConsiderationsStrong Growth at Low-RiskSummaryStrong Strategic Position Addressing high growth markets Focused, complete and technology-leading portfolio Critical mass, well functioning global organization Global footprint with activitiesInnovation is key Proven innovation leadership in industry 79 product launches in 2009 – 14 in Q1 2010 4-5% of revenue growth from new introduced productsStrong Financial Performance Exceed Q1 adjusted EPS on strong revenues Guidance 2010 Revenues:US 1,120 – 1,170 EPS, adj.:US 0.90 – 0.96- 23 -Sample & Assay Technologies
Thank you!- 24 -Sample & Assay Technologies
Roland Sackers, CFO-2-Sample & Assay Technologies. . on Form 20-F or Form 6-K to be filed with or furnished to the U.S. Securities and Exchange Commission. . MDx allows significant cost reduction in healthcare. Opportunities New platform launches 2010 - 2012
Northern Bank & Trust Co. Patriot Community Bank People's United Bank Pilgrim Bank Radius Bank RTN Federal Credit Union Santander StonehamBank TD Bank The Cooperative Bank The Savings Bank The Village Bank Walpole Cooperative Bank Wellesley Bank Winchester Co-operative Bank Abington Bank Bank of Canton Blue Hills Bank Boston Private Bank & Trust
M/s G.M. Kapadia & Co., Chartered Accountants Bankers HDFC Bank Ltd. (Primary Banker) Axis Bank Ltd. Bank of Baroda Bandhan Bank Ltd. Citibank N.A. CSB Bank Ltd. DCB Bank Ltd. Deutsche Bank ESAF Small Finance Bank ICICI Bank Ltd. IDFC Bank Ltd. Indian Bank RBL Bank Ltd. Saraswat Co-op Bank Ltd. State Bank of India Suryoday Small Finance Bank Ltd.
10. HDFC Bank Limited 11. ICICI Bank Ltd 12. Indian Overseas Bank 13. ING Vysya Bank 14. Kotak Bank -Virtual card 15. Shivalik Bank 16. Standard Chartered Bank 17. State Bank of Bikaner and Jaipur 18. State Bank of India 19. State Bank of Mysore 20. State Bank of Travencore 21. Syndicate Bank 22. The Federal Bank Ltd 23. The Karur Vysya Bank Ltd
miRNeasy Mini Handbook For purification of total RNA, including miRNA, from animal and human cells and tissues. Sample & Assay Technologies. QIAGEN Sample and Assay Technologies. QIAGEN is the leading provider of innovative sample and assay technologies, enabling . The QIAcube is preinstalled with protocols for
commerce bank eastern bank-east west bank everbank firstbank first hawaiian bank-first horizon bank firstmerit bank-first national of. nebraska first niagara flagstar bank f.n.b.corp. frost national bank fulton financial hancock bank iberiabank m b financial new york community banks old national, bank one west bank people's united bank raymond .
an ELISA TNF- assay to the DELFIA format. Conversion of other assays can be adapted from this example by referring to Table 3, which provides a specific recipe for the TNF- assay. 4 Table 2. Principles of ELISA and DELFIA TNF-α immunoassays ELISA DELFIA Assay schematic Assays An hTNF-ELISA assay was The hTNF-DELFIA assay used most of the
Oris CELL MIGRATION ASSAY – FIBRONECTIN COATED I. INTRODUCTION The Oris Cell Migration Assay – Fibronectin Coated is a reproducible, sensitive, and flexible assay that can be used to monitor cell migration. Formatted for a 96-well plate, the assay utilizes
①Each laboratory has 1 or 2 analysts with fire assay skills. ②A part-timer retired from regular analyst transfers his fire assay skills to younger analysts. The Sixth LBMA Assaying & Refining Conference 8-10 March 2015 JAPAN MINT (2) Tools and conditions for assay ① Some refiners were transferred assay skills from the Japan Mint.
